Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx in Advanced Mycosis Fungoides
NCT00074087Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2003
- Primary completion
- Jul 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in mycosis fungoides (MF), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Response Rate (Complete Response and Partial Response). Started Oct 2003; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT00074087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074087.